Compare Adaptive Biotechnologies Corp (ADPT) vs S&P500 ETF (SPY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs S&P500 ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while S&P500 ETF trades at $744.51. Which is the better fit depends on your goals.
| ADPT | SPY | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $759.55 |
52-Week Low | $10.24 | $620.34 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SPY trades at $747.62, up 0.38% with technical indicators showing mixed signals - moving averages are bullish while oscillators suggest caution. The ETF is approaching key resistance at $750-$758 levels. Recent market sentiment reflects debate between AI-driven growth optimism and concerns about market leverage and valuations.
The outlook remains cautiously optimistic with S&P 500 targets ranging from 8,000-8,800 by year-end, though strategists warn of potential 10-20% corrections. Key risks include excessive market leverage, high valuations, and sector rotation away from tech. Earnings growth and reasonable valuations may support further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
